Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036647
Status:
COMPLETED
Last Update Posted:
2018-01-10
First Post:
2002-05-13
Brief Title:
OSI-774 Tarceva in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Sponsor:
OSI Pharmaceuticals
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Randomized Placebo Controlled Study of OSI-774 Erlotinib HCl TarcevaTM in Patients With Incurable Stage IIIBIV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
Status:
COMPLETED
Status Verified Date:
2015-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIBIV non-small cell lung cancer compared to standard of care OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor EGFR OSI-774 is an investigational drug that has not yet been approved by the US Food and Drug Administration FDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None